HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GLYX-13 peptide

a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator

Also Known As:

TPPT-amide; rapastinel

Networked: 18 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - GLYX-13 peptide: 18

Experts

1.	Moskal, Joseph R: 5 articles (01/2019 - 11/2015)
2.	Banerjee, Pradeep: 3 articles (01/2022 - 01/2019)
3.	Gross, Amanda L: 3 articles (01/2019 - 11/2015)
4.	Kroes, Roger A: 3 articles (01/2019 - 11/2015)
5.	Stanton, Patric K: 3 articles (01/2019 - 11/2015)
6.	Meltzer, Herbert Y: 2 articles (01/2022 - 02/2016)
7.	Rajagopal, Lakshmi: 2 articles (01/2022 - 02/2016)
8.	Gass, Peter: 2 articles (12/2021 - 01/2017)
9.	Inta, Dragos: 2 articles (12/2021 - 01/2017)
10.	Lang, Undine E: 2 articles (12/2021 - 01/2017)

Related Diseases

1.	Substance Withdrawal Syndrome (Withdrawal Symptoms) 11/01/2022 - "The purpose of the present study was to evaluate the efficacy of rapastinel, an allosteric modulator of NMDA receptor function, to accelerate the loss of opioid withdrawal symptoms and blunt or prevent relapse to morphine conditioned place preference (CPP) in rats. "
2.	Memory Disorders (Memory Loss) 01/01/2022 - "Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice." 02/15/2016 - "These findings indicate that rapastinel, unlike ketamine, does not induce a declarative memory deficit in mice, and can prevent or reverse the ketamine-induced NOR deficit. " 02/15/2016 - "GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice." 01/01/2022 - "Rapastinel, a positive N-methyl-D-aspartate receptor (NMDAR) modulator with rapid-acting antidepressant properties, rescues memory deficits in rodents. "
3.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 11/01/2015 - "The effects of rapastinel on depression models, PEL, and most importantly on CFE demonstrate the therapeutic potential of rapastinel for the treatment of PTSD. " 11/01/2015 - "Since CFE is NMDA receptor modulated and neural circuitry in the medial prefrontal cortex (MPFC) regulates both depression and PTSD, studies were undertaken to examine the effects of rapastinel for its therapeutic potential in PTSD and to use rapastinel as a tool to study its underlying glutamatergic mechanisms. " 11/01/2015 - "Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats." 01/01/2017 - "We summarize and discuss current clinical and animal studies regarding the therapeutic potential of rapastinel not only in MDD but also in other psychiatric disorders, such as obsessive-compulsive disorder and posttraumatic stress disorder. "
4.	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/01/2018 - "Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder." 01/01/2017 - "We summarize and discuss current clinical and animal studies regarding the therapeutic potential of rapastinel not only in MDD but also in other psychiatric disorders, such as obsessive-compulsive disorder and posttraumatic stress disorder. " 03/01/2016 - "Among the modulators of the glutamatergic axis, promising compounds include: (i) ionotropic regulators of NMDA receptors: esketamine, AVP-923 and AVP-786, CERC-301, rapastinel (Glyx-13), NRX-1074 developed for depression, rapastinel and bitopertine developed for obsessive compulsive disorder, (ii) metabotropic glutamate receptors modulators: decoglurant and basimglurant developed for depression and mavoglurant developed for obsessive compulsive disorder. "
5.	Treatment-Resistant Depressive Disorder 10/01/2019 - "In addition, the study confirms the possible effectiveness of s-ketamine and rapastinel as treatment options in treatment-resistant depression. "

Related Drugs and Biologics

1.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
2.	Morphine (MS Contin)
3.	Opioid Analgesics (Opioids)
4.	6-chloro-2-(1-piperazinyl)pyrazine (CPP)
5.	Ketamine
6.	Phencyclidine (Angel Dust)
7.	Esketamine
8.	Antidepressive Agents (Antidepressants)
9.	N-Methylaspartate (NMDA)
10.	Propofol (Diprivan)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)